Evolus, Inc. (NASDAQ:EOLS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $16.00.

A number of equities analysts recently weighed in on EOLS shares. BTIG Research reiterated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research report on Wednesday, June 17th. Wall Street Zen downgraded shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th.

Institutional Trading of Evolus

Hedge funds have recently modified their holdings of the business. Divisadero Street Capital Management LP acquired a new position in Evolus during the third quarter worth $2,384,000. HighVista Strategies LLC raised its position in Evolus by 289.4% in the third quarter. HighVista Strategies LLC now owns 226,025 shares of the company’s stock worth $1,388,000 after acquiring an additional 167,983 shares in the last quarter. Potomac Capital Management Inc. acquired a new stake in Evolus in the fourth quarter valued at $939,000. Pinnacle Associates Ltd. lifted its holdings in Evolus by 15.9% in the fourth quarter. Pinnacle Associates Ltd. now owns 782,365 shares of the company’s stock valued at $5,203,000 after acquiring an additional 107,490 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of Evolus by 121.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 598,145 shares of the company’s stock worth $2,458,000 after purchasing an additional 327,926 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Stock Performance

EOLS stock remained flat at $6.90 during trading on Friday. The company had a trading volume of 534,868 shares, compared to its average volume of 725,787. The stock has a market cap of $454.40 million, a price-to-earnings ratio of -10.30 and a beta of 1.32. Evolus has a 1 year low of $3.86 and a 1 year high of $10.20. The company has a fifty day simple moving average of $6.43 and a 200-day simple moving average of $5.56.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $73.14 million during the quarter, compared to the consensus estimate of $72.52 million. During the same period last year, the firm earned ($0.30) earnings per share. As a group, research analysts forecast that Evolus will post -0.38 EPS for the current year.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.